All In Biotech

Drug Trial Radar · NCT07710196

A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis PigmentosaAssociated With Usher Syndrome

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Oct 23, 2026

Primary completion

Apr 2029

Study completion Apr 2029

Sponsor

Lead sponsor
Nacuity Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Foundation Fighting Blindness
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision. Participants will: Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.

Conditions

  • Retinitis Pigmentosa (RP)
  • Usher Syndrome

Interventions

  • PlaceboDrug

    Oral placebo tablet

  • NPI-001Drug

    Oral n-acetyl cysteine amide tablet (250mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ellipsoid Zone AreaTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Retina Foundation of the Southwest

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.